1. Home
  2. JFR vs CRVS Comparison

JFR vs CRVS Comparison

Compare JFR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Floating Rate Income Fund

JFR

Nuveen Floating Rate Income Fund

HOLD

Current Price

$7.64

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$12.68

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFR
CRVS
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
JFR
CRVS
Price
$7.64
$12.68
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$30.17
AVG Volume (30 Days)
682.7K
1.3M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
11.31%
N/A
EPS Growth
N/A
48.04
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.16
$3.71
52 Week High
$8.59
$26.95

Technical Indicators

Market Signals
Indicator
JFR
CRVS
Relative Strength Index (RSI) 54.17 52.58
Support Level $7.44 $11.13
Resistance Level $7.71 $14.00
Average True Range (ATR) 0.06 0.66
MACD -0.01 0.24
Stochastic Oscillator 50.00 83.26

Price Performance

Historical Comparison
JFR
CRVS

About JFR Nuveen Floating Rate Income Fund

Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: